NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden

NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden

Blog Article

Abstract Background Cancer patients experience increased risk of death from accident and suicide.Cognitive impairment induced by cancer-related inflammation and stress-related psychiatric symptoms may be underlying veste a frange sandro mechanisms.We therefore studied the association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of these outcomes.

Methods Following a cohort of 388,443 cancer patients diagnosed between October 2005 and December 2014 in Sweden, we ascertained dispense of aspirin or non-aspirin NSAIDs from 3 months before cancer diagnosis onward and defined the on-medication period as from date of drug dispense until the prescribed dosage was consumed.Follow-up time outside medicated periods and time from unexposed patients were defined as off-medication periods.We used Cox models to estimate hazard ratios (HRs) of death due to suicide or accident, by comparing the on-medication periods with off-medication periods.

Results In total, 29.7% of the cancer patients had low-dose aspirin dispensed and 29.1% had non-aspirin NSAIDs dispensed.

Patients with aspirin use were more likely to be male than patients without aspirin use.Compared with off-medication periods, there was a 22% lower risk of accidental death (N = 651; HR 0.78, 95% confidence interval [CI]: 0.

70 to 0.87) during on-medication periods with aspirin.The use of aspirin malibu relaxer was not associated with risk of suicide (N = 59; HR 0.

96, 95% CI: 0.66 to 1.39).

No association was noted between use of non-aspirin NSAIDs and the risk of suicide (N = 13; HR 0.95, 95% CI: 0.42 to 2.

18) or accidental death (N = 59; HR 0.92, 95% CI: 0.68 to 1.

26).Conclusions Intake of low-dose aspirin after cancer diagnosis was associated with a lower risk of unnatural deaths among cancer patients.